Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more
Stoke Therapeutics Inc (STOK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.099x
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has a cash flow conversion efficiency ratio of -0.099x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.37 Million) by net assets ($308.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Stoke Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Stoke Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Stoke Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stoke Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhongli Science and Technology Group Co Ltd
SHE:002309
|
0.184x |
|
Sparebanken Vest
OL:SVEG
|
0.056x |
|
IRSA Inversiones Y Representaciones
NYSE:IRS
|
0.000x |
|
The Greenbrier Companies Inc
F:G90
|
0.044x |
|
Phu Nhuan Jewelry JSC
VN:PNJ
|
-0.127x |
|
Rendong Holdings Co Ltd
SHE:002647
|
0.089x |
|
Guobo Electronics Co. Ltd. A
SHG:688375
|
N/A |
|
AEORF
PINK:AEORF
|
N/A |
Annual Cash Flow Conversion Efficiency for Stoke Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $229.02 Million | $-86.85 Million | -0.379x | +25.36% |
| 2023-12-31 | $159.56 Million | $-81.07 Million | -0.508x | -194.71% |
| 2022-12-31 | $184.85 Million | $-31.87 Million | -0.172x | +43.89% |
| 2021-12-31 | $217.78 Million | $-66.91 Million | -0.307x | -108.17% |
| 2020-12-31 | $286.08 Million | $-42.22 Million | -0.148x | -6.66% |
| 2019-12-31 | $224.43 Million | $-31.05 Million | -0.138x | -32.60% |
| 2018-12-31 | $105.07 Million | $-10.96 Million | -0.104x | -102.50% |
| 2017-12-31 | $-1.29 Million | $-5.38 Million | 4.167x | -- |